A detailed history of Financial Architects, Inc transactions in Novo Nordisk A S stock. As of the latest transaction made, Financial Architects, Inc holds 3,026 shares of NVO stock, worth $316,398. This represents 0.07% of its overall portfolio holdings.

Number of Shares
3,026
Previous 3,291 8.05%
Holding current value
$316,398
Previous $523,000 6.5%
% of portfolio
0.07%
Previous 0.08%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 09, 2023

SELL
$155.98 - $172.65 $41,334 - $45,752
-265 Reduced 8.05%
3,026 $489,000
Q1 2023

May 12, 2023

BUY
$132.34 - $159.14 $44,598 - $53,630
337 Added 11.41%
3,291 $523,000
Q3 2022

Nov 14, 2022

BUY
$95.28 - $116.93 $281,457 - $345,411
2,954 New
2,954 $294,000
Q2 2022

Aug 11, 2022

SELL
$103.24 - $121.81 $266,772 - $314,757
-2,584 Closed
0 $0
Q3 2021

Nov 12, 2021

SELL
$84.42 - $106.62 $7,935 - $10,022
-94 Reduced 3.51%
2,584 $248,000
Q2 2021

Aug 10, 2021

BUY
$67.66 - $84.76 $181,193 - $226,987
2,678 New
2,678 $224,000
Q3 2020

Nov 09, 2020

SELL
$63.69 - $70.22 $164,192 - $181,027
-2,578 Closed
0 $0
Q1 2019

May 13, 2019

BUY
$46.36 - $52.63 $3,384 - $3,841
73 Added 2.91%
2,578 $135,000
Q1 2019

May 03, 2019

SELL
$46.36 - $52.63 $3,384 - $3,841
-73 Reduced 2.83%
2,505 $131,000
Q2 2018

Aug 03, 2018

SELL
$44.29 - $50.42 $69,313 - $78,907
-1,565 Reduced 37.77%
2,578 $119,000
Q1 2018

Apr 23, 2018

BUY
$48.49 - $58.14 $19,396 - $23,256
400 Added 10.69%
4,143 $204,000
Q4 2017

Feb 12, 2018

BUY
$47.53 - $53.73 $41,588 - $47,013
875 Added 30.51%
3,743 $201,000
Q3 2017

Nov 01, 2017

BUY
$41.15 - $49.22 $14,937 - $17,866
363 Added 14.49%
2,868 $138,000
Q3 2017

Oct 23, 2017

BUY
$41.15 - $49.22 $103,080 - $123,296
2,505
2,505 $121,000

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $236B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Financial Architects, Inc Portfolio

Follow Financial Architects, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Financial Architects, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Financial Architects, Inc with notifications on news.